A clinical trial sponsored by the National Cancer Institute believes that anetumab ravtansine and MK-3475 may be capable of combating pleural mesothelioma. Researchers think that these antibodies are capable of stopping cancer cells from growing and spreading.

Treating Pleural Mesothelioma with Anetumab Ravtansine and MK-3475

The objective of this study is to determine if using the drug anetumab ravtansine alone or in combination with MK-3475 will work to combat pleural mesothelioma.

Drugs Involved

  • Target Icon
    Anetumab ravtansine – is a monoclonal antibody that targets and binds to mesothelin that is expressed by mesothelioma tumors. Researchers believe that anetumab ravtansine stops cancer cells from dividing and growing.
  • LinkIcon
    MK-3475 (pembrolizumab) – is a monoclonal immunoglobulin antibody. It works by binding with PD-1. MK-3475 activates T-cells in the immune system, which helps combat and kill tumor cells.

Researchers will be monitoring the safety of patients. They will analyze how well individuals tolerate the drugs used in the study. The investigators will also compare the progression-free survival and overall survival of the participants.

Get Help Enrolling in This Trial

Get Help Enrolling in This Trial - Form Image
The lack of treatment options for mesothelioma relative to those for other cancers make clinical trials an invaluable source of treatment. This clinical trial offers hope to pleural mesothelioma patients with a treatment plan that consists of the drugs anetumab ravtansine and MK-3475.

Reasons to get involved in this trial include:
  • Receive proven life-extending treatment
  • Researchers believe that MK-3475 is capable of killing cancer cells on its own or if combined with anetumab ravtansine
  • If a participant doesn’t have success with just being treated with MK-3475, they may experience being treated with both MK-3475 and anetumab ravtansine

Randomized Phase 1/Phase 2 Study

This clinical trial is currently recruiting for the Mayo Clinic located in Rochester, Minnesota. The study plans to enroll 134 people.

The clinical study will be divided into phase 1 and phase 2. During the trial, patients will be randomly placed into two groups.

  • 1
    Group 1 (Phase 1):
Patients in this group will receive pembrolizumab. Participants will be given the drug by an IV for 30 minutes on day 1 of the study.

  • 2
    Group 2 (Phase 2):
Participants in this group will be given anetumab ravtansine and pembrolizumab. On day 1 of the study, patients will receive the drugs via an IV. First, individuals will receive anetumab ravtansine for 1 hour. Pembrolizumab will be administered next for 30 minutes.

Enrollees in the study will have their treatment repeat every 21 days for potentially up to 2 years. Individuals in either group will continue to receive treatment as long as they do not show signs of toxicity or their disease doesn’t progress.

If a participant in Group 1 is showing signs of disease progression, upon approval, they may be given an opportunity to receive the same treatment as individuals in Group 2. They will be able to continue getting treatment with anetumab ravtansine and pembrolizumab until they show signs of disease progression or unsafe levels of toxicity.

After completing the study, participants will receive follow-ups for 12 months.

Meet the Lead Investigator: Dr. Mansfield

Head of this clinical trial is Dr. Aaron S. Mansfield. Dr. Mansfield is a researcher at the Mayo Clinic Cancer Center in Rochester, MN. He is actively involved in clinical trials that are focused on lung cancer and mesothelioma.

Dr. Mansfield has an interest in studying how tumors avoid destruction by the immune system. He hopes that his research and involvement in early-phase clinical trials will one day provide new life-saving treatments for mesothelioma patients.

Pleural Mesothelioma Patient: Is This Trial for You?

To participate in this clinical trial, a patient must have a confirmed diagnosis of malignant pleural mesothelioma. For phase 2 of the study, a patient’s tumors must showcase at least 30% of mesothelin expression.

All of the participants in the trial must have experienced chemotherapy treatment. It is acceptable for prior chemotherapy treatment to have included the drug bevacizumab. However, patients must not have been treated with a PD-1, PD-L1, or PD-L2 inhibitor.

Some other factors that may exclude a candidate are:

  • Receiving monoclonal antibody therapy within 4 weeks of starting the study.
  • Currently trying other investigational agents.
  • Patient hasn’t fully recovered from surgery or any other anti-cancer therapy.
  • Currently taking medications or substances that inhibit or induce CYP3A4 within 2 weeks of participation.

Before a patient believes that this is the right clinical trial for them, they must agree to all terms of the study. For example, this clinical trial may prohibit a patient from receiving certain types of treatment outside of the study.

For instance, patients may not be able to participate in:

  • Chemotherapy
  • Biological therapy
  • Immunotherapy
  • Radiation therapy
  • Any other form of investigation agents

Image of Nurse Jenna. For more information about this clinical trial, please contact Jenna Campagna. You can reach her at 888-385-2024 extension 102 or by emailing jenna@mesotheliomaguide.com.